From July 2025 Woosehill Medical Centre is taking part in a new NHS-funded weight management service across Buckinghamshire, Oxfordshire and Berkshire West (BOB ICB). This service is designed to support adults living with obesity who may benefit from NHS-approved weight management treatments including tirzepatide (Mounjaro) alongside structured lifestyle support.
Who is this service for?
This service is for adults who meet the BOB ICB eligibility criteria for NHS-funded obesity treatment.
To be eligible, you must meet all of the criteria below:
- Body Mass Index (BMI)
Have a body mass index (BMI) that meets the locally agreed criteria for the current phase of primary care access. This generally means a higher BMI combined with multiple weight-related health conditions, adjusted for ethnicity where relevant.- Year 1 of the service (2025 to 2026) – BMI of 40 or above, and 4 or more qualifying health conditions listed below (see below)
- Year 2 of the service (2026 to 2027) – BMI of 35 or above, and 4 or more qualifying health conditions listed below (see below)
- Year 3 of the service (phased from 2026 onwards)
You must have either:
A BMI of 40 or above with 3 qualifying health conditions, or
A BMI of 35 or above with 4 qualifying health conditions
For some ethnic groups, including South Asian, Chinese, other Asian, Middle Eastern, Black African or African Caribbean backgrounds, a lower BMI threshold applies, usually reduced by 2.5 BMI points.
- Qualifying health conditions are
| Health conditions | Definition for Initial Assessment |
| Atherosclerotic cardiovascular disease (ASCVD) | Established atherosclerotic CVD (ischaemic heart disease, cerebrovascular disease, peripheral vascular disease, heart failure) |
| Hypertension | Established diagnosis of hypertension and requiring blood pressure lowering therapy |
| Dyslipidaemia/ High cholesterol or triglycerides | Must be treated with lipid-lowering therapy, and the latest Cholesterol (LDL) should be 4.1 or higher, or triglycerides of 1.7 or higher in the past 12 months. |
| Obstructive Sleep Apnoea (OSA) | Established diagnosis of OSA (sleep clinic confirmation via sleep study) and treatment indicated i.e. meets criteria for continuous positive airway pressure (CPAP) or equivalent |
| Type 2 diabetes mellitus | Established type 2 diabetes mellitus |
Additional Notes:
- Blood test results for cholesterol/triglycerides must be from the last 12 months.
- Patients must be willing to attend regular reviews and commit to a behavioural support programme.
- Patients must not already be on a similar NHS treatment unless transferring with approval.
- Meeting these criteria does not guarantee treatment. All patients must be assessed by a clinician and must agree to take part in regular reviews and NHS behavioural support alongside any medication.
What do you need to do?
If you are eligible under the above criteria provided to us by the BOB ICB, we will contact you to offer you the opportunity. Even if you think you may be eligible, we won’t be able to offer it to you, as we can’t offer it to you if you don’t meet the above criteria.
Important notes
- Tirzepatide (Mounjaro) and similar medicines are only prescribed as part of a structured NHS pathway where lifestyle and behavioural support are provided alongside medication.
- Continued treatment is reviewed by clinicians and takes into account your engagement with the programme and progress, including weight changes and overall health benefits.
- Private requests for weight loss medicines cannot be substituted for NHS qualifying criteria.
- Continued access to treatment depends on your engagement and achieving a minimum of 5% weight loss after 6 months.
Find more information
- NHS England » Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity
- 1 Recommendations | Tirzepatide for managing overweight and obesity | Guidance | NICE
- Medicines and surgery | Overweight and obesity management | Guidance | NICE
- Overview | Tirzepatide for managing overweight and obesity | Guidance | NICE
- GPhC guidelines
- Journal of the American Association of Nurse Practitioners